MRSN vs. BMEA, MREO, CRBP, LXRX, AMRN, RVNC, ESPR, PEPG, TRDA, and NATR
Should you be buying Mersana Therapeutics stock or one of its competitors? The main competitors of Mersana Therapeutics include Biomea Fusion (BMEA), Mereo BioPharma Group (MREO), Corbus Pharmaceuticals (CRBP), Lexicon Pharmaceuticals (LXRX), Amarin (AMRN), Revance Therapeutics (RVNC), Esperion Therapeutics (ESPR), PepGen (PEPG), Entrada Therapeutics (TRDA), and Nature's Sunshine Products (NATR). These companies are all part of the "pharmaceutical preparations" industry.
Biomea Fusion (NASDAQ:BMEA) and Mersana Therapeutics (NASDAQ:MRSN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, institutional ownership, community ranking, earnings, profitability, valuation and analyst recommendations.
Biomea Fusion has a beta of -0.33, meaning that its share price is 133% less volatile than the S&P 500. Comparatively, Mersana Therapeutics has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500.
96.7% of Biomea Fusion shares are owned by institutional investors. Comparatively, 93.9% of Mersana Therapeutics shares are owned by institutional investors. 26.3% of Biomea Fusion shares are owned by insiders. Comparatively, 12.5% of Mersana Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Biomea Fusion presently has a consensus price target of $53.25, indicating a potential upside of 331.17%. Mersana Therapeutics has a consensus price target of $6.29, indicating a potential upside of 81.67%. Given Mersana Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Biomea Fusion is more favorable than Mersana Therapeutics.
In the previous week, Biomea Fusion had 5 more articles in the media than Mersana Therapeutics. MarketBeat recorded 8 mentions for Biomea Fusion and 3 mentions for Mersana Therapeutics. Mersana Therapeutics' average media sentiment score of 0.07 beat Biomea Fusion's score of 0.00 indicating that Biomea Fusion is being referred to more favorably in the media.
Mersana Therapeutics received 214 more outperform votes than Biomea Fusion when rated by MarketBeat users. Likewise, 65.78% of users gave Mersana Therapeutics an outperform vote while only 59.26% of users gave Biomea Fusion an outperform vote.
Biomea Fusion has higher earnings, but lower revenue than Mersana Therapeutics. Biomea Fusion is trading at a lower price-to-earnings ratio than Mersana Therapeutics, indicating that it is currently the more affordable of the two stocks.
Biomea Fusion has a net margin of 0.00% compared to Biomea Fusion's net margin of -465.80%. Mersana Therapeutics' return on equity of -64.37% beat Biomea Fusion's return on equity.
Summary
Biomea Fusion beats Mersana Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Mersana Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRSN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MRSN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mersana Therapeutics Competitors List
Related Companies and Tools
